cas 59489-71-3|| where to buy 5-bromopyrazin-2-amine

Nom du produit:5-bromopyrazin-2-amine

IUPAC Name:5-bromopyrazin-2-amine

Unité d'emballage	Stock disponible	Prix($)
CM104262-100g	in stock	ǲɐ
CM104262-500g	in stock	ȌƋȌ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 59489-71-3 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:59489-71-3; Formule moléculaire:C4H4BrN3; Point de fusion:-; Code SMILES:NC1=NC=C(Br)N=C1; Densité:

: Numéro de catalogue:CM104262; Poids moléculaire:174; Point d'ébullition:274.2°C at 760 mmHg; N° Mdl:MFCD00235015; Stockage:Keep in dark place, store at 2-8°C.

: Pyrazines; Pyrazine is a heterocyclic aromatic organic compound with chemical formula C4H4N2. The marketed pyrazine drugs are mainly distributed in the field of anti-tumor and anti-infection. In recent years, there have been many new drugs in various fields, and there are some new target drugs worthy of attention.; pyrazine,pyrazine price; if you want to know the latest news about pyrazine and pyrazine price, please come to our website and get a quote for free.

: Zegocractin; CalciMedica announces positive topline data from phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP). The trial met primary objective with statistically significant dose response. Calcium release–activated calcium (CRAC) channels are involved in activating T cells, and responsible for regulating calcium-dependent inflammatory pathways or tissue cell injury pathways. AP is a potentially life-threatening inflammatory disease of the pancreas featured by aberrant signaling of calcium.
CalciMedica’s Auxora is a potent and selective intravenous formulated CRAC channel inhibitor containing the active ingredient Zegocractin. It is being developed for the treatment of acute inflammatory and immunologic illnesses, including severe AP, AIPT, AKI, and severe acute respiratory diseases including AHRF, and ARDS.